Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Game changer tomorrow so topped up and chillin.
GLA
And to back it up, final top ups made... gla!
Yep, for me now the clues outweigh the queries, this is happening and the appetite for lfts is only growing.
That sounds like our test is in the running.
Be interesting tomorrow when 8bn tender awards are released.
Rapid Covid test from Omega stacks up well against ‘gold standard’ PCR
By Kristy Dorsey @KristyDorsey
Rapid Covid test from Omega stacks up well against ‘gold standard’ PCR
Rapid Covid test from Omega stacks up well against ‘gold standard’ PCR
A rapid Covid test made by Scotland’s Omega Diagnostics has been shown to detect the presence of the virus in more than 96 per cent of those whose infection would be picked up by “gold standard” PCR testing carried out in a laboratory.
New independent verification has shown that the Mologic lateral flow antigen test for Covid-19, which has been CE marked by Omega for sale under its Visitect brand, has 96.4% sensitivity when compared to laboratory PCR testing. This means that out of 100 infected patients identified by PCR testing, deemed to be the most accurate available, the Mologic test would return the same result for more than 96 of them.
The verification was carried out by FIND, a World Health Organisation collaborating centre for diagnostic technology evaluation. The study was carried out with 665 people in Germany who took their own swab samples.
READ MORE: Omega Diagnostics adds to Covid testing repertoire
Omega described the results as “best-in-class performance”. The findings will be significant in on-going discussions about the use of PCR, which is more expensive and time-consuming, versus lateral flow tests that produce results within minutes.
“This is great news for the Mologic test, which we are now producing under our Visitect brand,” Omega chief executive Colin King said.
“It is significant that the test has been shown to have high diagnostic accuracy on self-collected swab specimens. Rapid diagnostic tests play a crucial role in breaking the spread of infection in the community and we are delighted to be a leading manufacturer of these home-grown tests.”
READ MORE: Omega to receive up to £374m from UK test deal
Omega is set to receive up to £374 million to manufacture rapid Covid19 tests under contract on behalf of the Department for Health and Social Care (DHSC). A final decision has yet to be made on which test or tests the UK Government will choose as part of its national testing strategy, though Bedfordshire-based Mologic’s is among those under consideration.
If the Mologic test gets the Government go-ahead, Omega’s production facilities at its headquarters in Alva, Clackmannanshire, will produce it both for the DHSC and for sale under the Visitect brand. As part of its contract with the UK Government, Omega is due to have capacity to produce up to two million tests per week by the end of this month.
Shares in Omega closed yesterday’s trading 2.15p higher at 71.65p.